ITMCTR2000003158招募中1 期
Study on the Therapeutic Effect and Mechanism of Bushen Yisui Capsules Against Multiple Sclerosis with Depression Based on Multi-modality Analysis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 —（—）
- 性别
- All
入选标准
- •1. Meets the 2010 McDonald MS diagnostic criteria;
- •2. Meet the International Standard for Classification and Diagnosis of Diseases (ICD-10 diagnostic criteria for mild and moderate depression (F32) depression, first diagnosis, first treatment;
- •3. HAMD-24 item scale score >= 20 points and < 35 points;
- •4. Age over 18 years and under 65 years;
- •5. MRI demyelination site in the skull;
- •6. Subjects volunteered and signed informed consent.
排除标准
- •1. Other treatments were performed before the start of this study;
- •2. Patients with acute MS who have a cortical state or coma;
- •3. Suffering from severe heart, liver and kidney dysfunction and other diseases that affect the stability of vital signs;
- •4. Patients during pregnancy or lactation;
- •5. People who have a significant tendency to commit suicide;
- •6. Serious adverse reactions in nuclear magnetic (MRS, DTI) scans that make the examination impossible;
- •7. In any other situation that the researcher considers unsuitable to participate in this trial, such as failure to cooperate with nuclear magnetic scanning as required by the research;
- •8. Patients with MS who have entered a relapse period during follow-up.
研究者
相似试验
招募中
不适用
Effects of body electrical stimulation after the stomach reduction surgeryMorbidly obese patients undergoing bariatric surgeryC18.654.726.500.700E02.065.062RBR-99qw5hniversidade Federal de São Carlos
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)EUCTR2018-000462-11-ESBristol-Myers Squibb International Corporation250
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10080083Term: Advanced lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000462-11-BEBristol-Myers Squibb International Corporation250
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab incombination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer(NSCLC)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer(NSCLC)MedDRA version: 20.0Level: LLTClassification code 10007096Term: Cancer of lungSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000462-11-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO250
进行中（未招募）
1 期
A Study exploring the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Non-Small Cell Lung Cancer (NSCLC)Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10080083Term: Advanced lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000462-11-ROBristol-Myers Squibb International Corporation250